Tag: Arch Biopartners
March 19, 2019
Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia
Arch Biopartners (TSXV:ARCH,OTCQB:ACHFF) has announced it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase... October 29, 2018
Arch Biopartners Provides Toxicology Update for Metablok
Arch Biopartners (TSXV:ARCH;OTCQB:ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s... May 8, 2018
Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients
Arch Biopartners (TSX Venture:ARCH) (OTCBB:ACHFF), announced today it completed a successful pre-IND (Investigational New Drug) meeting via teleconference on April... March 27, 2018
Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569
Arch Biopartners (TSXV:ARCH) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and... February 27, 2018
Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio
Arch Biopartners (TSXV:ARCH) a portfolio-based biotechnology company, today announced CSBio of Menlo Park, California, has started the good manufacturing practice... January 26, 2018
Arch Biopartners Announces Non Brokered Private Placement Financing
Arch Biopartners (TSXV:ARCH) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 2,500,000... September 28, 2017